본문으로 건너뛰기
← 뒤로

Management of adverse events associated with TROP2-targeted antibody-drug conjugates in cancer patients.

Critical reviews in oncology/hematology 2026 Vol.220() p. 105153

He Z, Luo Z, Dai P, Wang X, Yang J

📝 환자 설명용 한 줄

Antibody-drug conjugates (ADCs) constitute an innovative category of anti-tumor therapeutics that selectively deliver cytotoxins to tumor cells, improving efficacy and reducing toxicity in comparison

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA He Z, Luo Z, et al. (2026). Management of adverse events associated with TROP2-targeted antibody-drug conjugates in cancer patients.. Critical reviews in oncology/hematology, 220, 105153. https://doi.org/10.1016/j.critrevonc.2026.105153
MLA He Z, et al.. "Management of adverse events associated with TROP2-targeted antibody-drug conjugates in cancer patients.." Critical reviews in oncology/hematology, vol. 220, 2026, pp. 105153.
PMID 41587589

Abstract

Antibody-drug conjugates (ADCs) constitute an innovative category of anti-tumor therapeutics that selectively deliver cytotoxins to tumor cells, improving efficacy and reducing toxicity in comparison to systemic therapy. TROP2 serves as a significant target for ADCs in cancer detection and treatment. TROP2-targeted ADCs have shown promising efficacy in cancer therapy. However, it is essential to monitor expected adverse effects to ensure the anti-tumor efficacy and safety. This review clarifies the mechanisms and toxicological profiles of TROP2-targeted medicines based on clinical trials and recommendations, with the aim of providing solutions for the prevention, detection, and management of related adverse events.

MeSH Terms

Humans; Immunoconjugates; Neoplasms; Antigens, Neoplasm; Cell Adhesion Molecules; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions

같은 제1저자의 인용 많은 논문 (5)